Baysient’s web-based applications, iDose and T3 were specifically developed to facilitate the dosing of biological agents by integrating real patient’s clinical characteristics. Both softwares use Bayesian models, routine lab results, and demographics to individualize dosing to a specified target trough level.

iDose has shown statistically significant and clinically meaningful reductions in both primary non-response (treatment failure during the first three doses) and secondary non-response (failure after the fourth dose) are achieved when the software aids medical decision making. T3 has been validated against iDose and shown to provide equivalent dose recommendations.

Standard Dosing vs. Dosing Using iDose and T3

Standard dosing follows a one-size-fits-all approach for disease treatment and prevention. Standard dosing only considers the amount of drug administered to the patient at set times (every 8 weeks). Along with the amount of drug administered to the patient, this approach does not tailor the medical treatment to the individual characteristics of each patient, which may lead to drug failure. 

iDose and T3 consider both the amount of drug and how long the drug stays in the patient’s body. Different patients clear (eliminate) infliximab (IFX) at significantly different rates. The differences between patients is what drives iDose and T3 dose recommendations. For patients that clear IFX quickly, there is a very high probability that the treatment will fail which is reflected in the historically high treatment failure rates (20-30% failure in induction and 10-20% per year in maintenance). 

What’s the Clinical Difference Between iDose and T3?

The main difference between iDose and T3 is that iDose may be used for both IFX induction (first three doses) and maintenance (all doses after the third dose). iDose is best for early treatment because patients are changing very quickly during induction. iDose can also use data that was not collected at trough.  The flexibility of iDose provides timely information that is necessary during induction. 

On the other hand, T3 is for maintenance only, with patients having regular dosing intervals of at least four (4) weeks. T3 is an algorithm that will determine the individual half-life of a drug for each patient. By having this information, an accurate indication of the length of time until the drug concentrations fall below the target concentration can be determined. This will allow the drug to be prescribed at a specific dose that ensures it is present long enough and is at a high enough exposure to treat the patient’s condition. T3 is easy to use but does require drug concentrations taken at trough.

Do iDose and T3 Use Laboratory and IFX Concentration Values?

For iDose, an IFX concentration is a preferred input. iDose inputs include a variety of other IFX clearance covariates such as patient weight and albumin. Inputs default to nominal values for missing data. iDose performance is enhanced when individual patient concentration data are provided. However, in the treatment of acute severe ulcerative colitis patients, after entry of all available data, iDose has been used successfully prior to the first IFX dose to determine effective treatment plans.

For T3, an IFX concentration is a necessary T3 input. T3 inputs include only one other IFX covariate: weight. Missing data do not default to nominal values. 

Ready to Get Started?

Baysient’s easy-to-use, intuitive apps provide individualized maintenance dosing calculations at your fingertips. Start improving your patient outcomes today!

With iDose: $20 per patient/per month.

With T3: $25 unlimited patients/per month.